 Lymphoma, Large B-Cell, Diffuse
"Lymphoma, Large B-Cell, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Descriptor ID |
D016403
|
| MeSH Number(s) |
C04.557.386.480.150.585 C15.604.515.569.480.150.585 C20.683.515.761.480.150.585
|
| Concept/Terms |
Lymphoma, Large B-Cell, Diffuse- Lymphoma, Large B-Cell, Diffuse
- Diffuse Large-Cell Lymphoma
- Diffuse Large Cell Lymphoma
- Diffuse Large-Cell Lymphomas
- Large-Cell Lymphomas, Diffuse
- Lymphomas, Diffuse Large-Cell
- Diffuse, Large B-Cell, Lymphoma
- Histiocytic Lymphoma
- Histiocytic Lymphomas
- Lymphomas, Histiocytic
- Histiocytic Lymphoma, Diffuse
- Diffuse Histiocytic Lymphoma
- Diffuse Histiocytic Lymphomas
- Histiocytic Lymphomas, Diffuse
- Lymphoma, Diffuse Histiocytic
- Lymphomas, Diffuse Histiocytic
- Large Lymphoid Lymphoma, Diffuse
- Large-Cell Lymphoma
- Large Cell Lymphoma
- Large-Cell Lymphoma, Diffuse
- Large Cell Lymphoma, Diffuse
- Lymphoma, Diffuse Large-Cell
- Lymphoma, Diffuse Large Cell
- Lymphoma, Histiocytic
- Lymphoma, Histiocytic, Diffuse
- Lymphoma, Large Cell, Diffuse
- Lymphoma, Large Lymphoid, Diffuse
- Lymphoma, Large-Cell
- Large-Cell Lymphomas
- Lymphoma, Large Cell
- Lymphomas, Large-Cell
- Lymphoma, Large-Cell, Diffuse
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large B-Cell, Diffuse".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large B-Cell, Diffuse".
This graph shows the total number of publications written about "Lymphoma, Large B-Cell, Diffuse" by people in UAMS Profiles by year, and whether "Lymphoma, Large B-Cell, Diffuse" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 2 | 0 | 2 | | 2021 | 2 | 0 | 2 | | 2020 | 2 | 1 | 3 | | 2019 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2017 | 2 | 1 | 3 | | 2016 | 3 | 0 | 3 | | 2015 | 4 | 0 | 4 | | 2014 | 3 | 0 | 3 | | 2013 | 3 | 0 | 3 | | 2011 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2008 | 2 | 0 | 2 | | 2007 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles over the past ten years.
-
McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329.
-
Yu T, Xu-Monette ZY, Lagoo A, Shuai W, Wang B, Neff J, Carrillo LF, Carlsen ED, Pina-Oviedo S, Young KH. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma. Front Immunol. 2024; 15:1335689.
-
Abadir S, Iska S, Bunting ST, Fu CL. An Atypical relapsing follicular lymphoma to composite Hodgkin's lymphoma. BMJ Case Rep. 2023 Dec 28; 16(12).
-
Hoover A, Zimmerman JAO, Wiese S, Modi A. Evaluation of Empiric Vancomycin for Fevers During High-dose Cytarabine Administration. J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e1010-e1014.
-
Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 10 01; 106(10):2667-2672.
-
Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021 03 01; 106(3):730-735.
-
Stremenova Spegarova J, Lawless D, Mohamad SMB, Engelhardt KR, Doody G, Shrimpton J, Rensing-Ehl A, Ehl S, Rieux-Laucat F, Cargo C, Griffin H, Mikulasova A, Acres M, Morgan NV, Poulter JA, Sheridan EG, Chetcuti P, O'Riordan S, Anwar R, Carter CR, Przyborski S, Windebank K, Cant AJ, Lako M, Bacon CM, Savic S, Hambleton S. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood. 2020 08 27; 136(9):1055-1066.
-
Pina-Oviedo S, Bellamy WT, Gokden M. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases. Ann Diagn Pathol. 2020 Oct; 48:151610.
-
Salama A, Marcellino BK, Saad AG, Teruya-Feldstein J, Firpo-Betancourt A, Abulsayen HA, Grada Z, Hassan M, El Jamal SM. Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma. Appl Immunohistochem Mol Morphol. 2020 08; 28(7):e63-e64.
-
Saad AG, Grada Z, Bishop B, Abulsayen H, Hassan M, Firpo-Betancourt A, Teruya-Feldstein J, Fraig M, El Jamal SM. nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin. Appl Immunohistochem Mol Morphol. 2019 10; 27(9):644-648.
-
Jiang XY, Shen HR, Ge CW, Li J, Zhou DB. [Clinical role of Morphology in Diagnosing Bone Marrow Involvement of Diffuse Large B Bell Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr; 27(2):421-425.
-
El Jamal SM, Grada Z, El Dinali MH, Zhou H, Hassan SY, Saad AG, Gibson B, Zhou X, Abulsayen HA, Khadra HS, Friedman J, Shalaby H, Kadi A, Megahed M, Emberesh M, Teruya-Feldstein J, Firpo-Betancourt A, Haikel Y, Fraig M, Hassan M. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type. Lab Invest. 2019 04; 99(4):539-550.
-
Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. Ann Hematol. 2017 Nov; 96(11):1867-1871.
-
Pandey S, Rosenbaum E, Cottler-Fox M, Harville TO. Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches. Ann Clin Lab Sci. 2017 May; 47(3):315-318.
-
Ikoma N, Badgwell BD, Mansfield PF. Multimodality Treatment of Gastric Lymphoma. Surg Clin North Am. 2017 Apr; 97(2):405-420.
-
Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan KL, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch. 2017 Jan; 470(1):113-117.
-
Zhang W, Bai JF, Zuo MX, Cao XX, Chen M, Zhang Y, Han X, Zhong DR, Zhou DB. PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Med. 2016 11; 5(11):3077-3084.
-
Jabbour G, El-Mabrok G, Al-Thani H, El-Menyar A, Al Hijji I, Napaki S. Primary Breast Lymphoma in a Woman: A Case Report and Review of the Literature. Am J Case Rep. 2016 Feb 19; 17:97-103.
-
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma. 2016 10; 57(10):2359-69.
-
Kendrick S, Tus K, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, Scott DW, Rimsza LM. Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leuk Lymphoma. 2016; 57(3):717-20.
-
Yang G, Zhang Q, Kong Y, Xie B, Gao M, Tao Y, Xu H, Zhan F, Dai B, Shi J, Wu X. Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2015 Nov; 47(11):925-31.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|